Conversion Labs to Present at the H.C. Wainwright Virtual BioConnect Conference on January 11, 2021
Conversion Labs, Inc. (NASDAQ: CVLB) has been invited to present at H.C. Wainwright’s BioConnect Conference, scheduled for January 11-14, 2021. The company will discuss its significant achievements, including a record annualized revenue run-rate of $53.9 million and a remarkable 517% increase in annual recurring revenue (ARR) from subscriptions, reaching $23.0 million. Key topics will include the upcoming launch of Nava MD™, its new teledermatology brand. The presentation will be available on-demand, and the company encourages registration for virtual one-on-one meetings with analysts and investors.
- None.
- None.
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has been invited to present at H.C. Wainwright’s BioConnect Conference being held virtually on January 11-14, 2021.
The company’s presentation will be available on-demand via the H.C. Wainwright conference portal here and in the investor relations section at ConversionLabs.com beginning at 6:00 a.m. Eastern time on Monday, January 11.
Conversion Labs’ head of corporate development, Corey Deutsch, will discuss how the company’s recent accomplishments have translated into strong demand for its direct-to-consumer telemedicine products. This has resulted in a record annualized revenue run-rate of
He will also discuss the upcoming launch of Nava MD™, the company’s first teledermatology and over-the-counter skincare brand featuring patented and clinically proven formulations.
Deutsch and Conversion Labs CEO Justin Schreiber will participate in virtual one-on-one meetings with institutional analysts and investors throughout the conference.
Register for the conference here. To schedule a one-on-one meeting with the company, please contact your H.C. Wainwright representative. To learn more about Conversion Labs, please contact Ron Both of CMA at (949) 432-7557 or submit your request here.
About H.C. Wainwright
H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998. For more information about H.C. Wainwright, visit www.hcwco.com.
About Conversion Labs
Conversion Labs, Inc. is a telemedicine company with a portfolio of online direct-to-consumer brands. The company’s brands combine virtual medical treatment with prescription medications and unique over-the-counter products. Its network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S. To learn more, visit Conversionlabs.com.
Important Cautions Regarding Forward-Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects -- both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as "believe," "expect," "anticipate," "should," "planned," "will," "may," "intend," "estimated," and "potential," among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to Conversion Labs, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.
Company Contact
Conversion Labs
Juan Manuel Piñeiro Dagnery
CFO
Email Contact
Media and Investor Relations Contact
Ron Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7566
Email Contact
FAQ
What significant revenue achievement did Conversion Labs report in January 2021?
When is the BioConnect Conference where Conversion Labs will present?
What is Nava MD™ and when will it be launched?
How can I access Conversion Labs' presentation at the BioConnect Conference?
Who will represent Conversion Labs at the BioConnect Conference?
